Q2 EPS Estimates for Bone Biologics Cut by Zacks Small Cap

Bone Biologics Corp. (NASDAQ:BBLG) – Stock analysts at Zacks Small Cap dropped their Q2 2025 earnings per share (EPS) estimates for Bone Biologics in a note issued to investors on Wednesday, June 11th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings of ($1.93) per share for the quarter, down from their prior forecast of ($1.92). The consensus estimate for Bone Biologics’ current full-year earnings is ($5.00) per share. Zacks Small Cap also issued estimates for Bone Biologics’ Q3 2025 earnings at ($1.79) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($7.30) EPS and FY2026 earnings at ($5.81) EPS.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings results on Monday, May 12th. The company reported ($1.92) EPS for the quarter, beating analysts’ consensus estimates of ($2.88) by $0.96.

Bone Biologics Price Performance

Shares of NASDAQ BBLG opened at $5.08 on Monday. Bone Biologics has a 12 month low of $3.42 and a 12 month high of $25.50. The stock has a 50-day moving average price of $4.55 and a two-hundred day moving average price of $5.41.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.